Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 10/20 | 0.59 |
| ▸ | AGXT | P21549 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26821713 | 0.85 | KIF11 (0.73) | KIF11AGXTDHODHKDM1ABACE1 | |
| SCHEMBL16068255 | 0.81 | KIF11 (0.67) | KIF11AGXTDHODHKDM1APTPN1 | |
| SCHEMBL11898508 | 0.80 | HSD17B1 (0.43) | MGLL | |
| SCHEMBL9937753 | 0.78 | MAOA (0.48) | MGLL | |
| SCHEMBL28128350 | 0.78 | PTPN1 (0.62) | KIF11AGXTDHODHPTPN1MAOB | |
| SCHEMBL66448 | 0.76 | TSHR (0.54) | MGLL | |
| SCHEMBL23748371 | 0.76 | KIF11 (0.59) | KIF11AGXTDHODHPTPN1MAOB | |
| SCHEMBL4488129 | 0.76 | KIF11 (0.59) | KIF11AGXTDHODHKDM1ABACE1 | |
| SCHEMBL631923 | 0.76 | KIF11 (0.63) | KIF11AGXTDHODHKDM1AMAOB | |
| SCHEMBL5050189 | 0.76 | KIF11 (0.59) | KIF11AGXTDHODHKDM1ABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906518-B2 | [(3aR,4R,6R,6aR)-6-(6-amino-2-methoxy-9H-purin-9yl)tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]methanol; improved oral absorption | CBT DEVELOPMENT LIMITED (GB) | 2011-03-15 | — | — | US | disclosed |
| EP-2066685-A2 | NOVEL 2',3'-METHYLIDENE ACETYL ADENOSINE PRODRUGS FOR USE AS PRODRUGS FOR ADENOSINE RECEPTOR AGONISTS | BIOVITRUM AB (publ) (SE) | 2009-06-10 | — | — | EP | disclosed |
| US-20080027081-A1 | Therapeutic compounds | BIOVITRUM AB (PUBL) | 2008-01-31 | — | — | US | disclosed |
| WO-2008000743-A2 | NOVEL 2',3'-METHYLIDENE ACETYL ADENOSINE PRODRUGS FOR USE AS PRODRUGS FOR ADENOSINE RECEPTOR AGONISTS | BIOVITRUM AB (PUBL) (SE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027081-A1 | Therapeutic compounds | ADORA2A, ADORA3, ADORA2B | KIF11 4819/4885AGXT 2870/4885DHODH 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.